109 results
Page 2 of 6
8-K
EX-10.1
vk1m9vljd3xifh
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
424B5
o2t4ixb
24 Mar 22
Prospectus supplement for primary offering
4:15pm
424B5
q3xnrklqjfq
20 Aug 21
Prospectus supplement for primary offering
4:46pm
8-K
EX-10.1
m6hh pvqp6d2vtybuv24
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
424B3
q3m4s7jv77uq 9fsmql
12 Apr 21
Prospectus supplement
1:44pm
S-3
nwo5d zlx
2 Apr 21
Shelf registration
12:00am
D
k4q80dbkcg81pf
19 Feb 21
$10.24M in equity / options, sold $10.24M, 18 investors
9:26am
8-K
EX-10.1
tlwm cu7gfa9z5re
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-10.2
2i2ouzu5l5q6p37 wp3
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-10.1
ft69m ff2
13 Oct 20
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
9:30am
424B4
kecy14n58jgxogtmit
5 Oct 20
Prospectus supplement with pricing info
4:16pm